Computational (in silico) modeling and simulation (M&S) are powerful tools that complement traditional methods for gathering evidence–including bench-top (in vitro) testing, and animal or clinical (in vivo) studies–about products regulated by FDA or for developing FDA policy.
FDA scientists routinely review results from M&S studies submitted by industry and use M&S approaches for scientific research and regulatory decision-making.
FDA’s Office of the Chief Scientist formed the Modeling and Simulation Working Group in 2016. The group includes nearly 200 FDA scientists who are supporting the implementation of M&S in the regulatory review process across FDA, among other goals.
In November 2022, FDA published a new report, Successes and Opportunities in Modeling & Simulation for FDA. The report:
- Elucidates how and where M&S is used across FDA, and the type and purpose of M&S used
- Presents a selection of M&S case studies from across nearly all FDA centers, which demonstrate how M&S is playing a tangible role in FDA fulfilling its mission
- Identifies opportunities for FDA to better harness M&S in upcoming years by embracing computational advances and new (and big) data streams to develop improved public health solutions
Contact the corresponding authors with questions about this report.
Contact ModSimWG leadership with general questions about modeling and simulation at FDA.
Press/media: Contact FDA’s Office of Media Affairs at firstname.lastname@example.org or call 301-796-4540.